Abstract
Background
Limited evidence exists to evaluate the clinical and economic burden of treating hospitalized surgical patients experiencing peripheral intravenous catheter (PIVC)–associated complications.
Objective
To estimate the prevalence of PIVC-associated complications and compare the healthcare resource use and cost between surgical inpatients with and without a PIVC-associated complication.
Methods
This retrospective cohort study used a large, geographically diverse, hospital-based US database (Premier Healthcare Database). Hospitalized adult (≥18 years) and pediatric (<18 years) patients undergoing a surgery between January 1, 2019, and December 31, 2023, without the use of central line access device were included.
Results
The analysis included 6 992 120 adult and 159 256 pediatric patients. In the adult cohort, the prevalence of PIVC-associated complications was 0.7%. Patients with complications were older (mean, 64.2 vs 55.2 years) and more likely to be men (53.1% vs 36.6%) than those without complications (both P < .01). Patients with complications were 46% more likely to be readmitted for any reason (odds ratio [OR], 1.46; 95% confidence interval [CI], 1.42-1.50), had longer length of stay (LOS) by 5.52 days, and incurred higher costs by $19 074 than patients without complications, after adjusting for covariates (all P < .01). In the pediatric cohort, the prevalence of PIVC-associated complications was 0.5%. Patients with complications were younger (mean, 8.6 vs 9.6 years) and more likely to be Black (19.9% vs 15.6%) than those without complications (both P < .01). Patients with complications were 115% more likely to be readmitted for any reason within 30 days after discharge (OR, 2.15; 95% CI, 1.73-2.67), had longer LOS by 4.50 days, and incurred higher costs by $16 052 than patients without complications, after adjusting for covariates (all P < .01).
Discussion
While the overall prevalence of PIVC-associated complications is around 1%, this still amounts to a significant number of patients as most patients undergoing an inpatient surgical procedure would have a PIVC placed. The study results call for stakeholders to establish a process for decreasing complications related to PIVCs.
Conclusions
In both adult and pediatric cohorts, patients with PIVC-associated complications had significantly higher total hospitalization cost, LOS, and 30-day readmission risks than those without complications.
Keywords: peripheral intravenous catheter, complication, cost, readmission, bloodstream infection
BACKGROUND
Over 170 million peripheral intravenous catheters (PIVCs) are inserted every year and complications with their use are not uncommon.1,2 Complications associated with PIVCs include but are not limited to catheter-related bloodstream infection (BSI), catheter occlusion, phlebitis, and infiltration.1,3 Among these, the most serious complication associated with PIVC is BSI.1,4 Because the protective barrier effect of the skin is breached when a PIVC is inserted, bacteria can enter the bloodstream or cause local infections (eg, cellulitis, soft tissue infection).1,4,5 Therefore, common pathogens associated with PIVC-associated BSI are normal skin flora or those commonly found in hospital settings (eg, coagulase-negative Staphylococci and Staphylococcus aureus).6 A recent study of 110 PIVC tips in Portugal reported that 30% were contaminated with pathogens, of which the majority was Staphylococcus species with high pathogenicity and resistance to antibiotics.7 The prevalence of PIVC-associated BSI in the United States is estimated to be around 0.2%.8 However, this percentage may be underreported because PIVCs are not consistently tracked for BSI in national surveillance systems.9,10 Not only can catheter-related BSI significantly prolong hospital stay and increase healthcare cost, but it can also put patients at risk of developing sepsis, multi-organ failure, and mortality.1,11,12
Other complications such as occlusion and phlebitis can lead to failure and premature removal of catheters.13 Catheter failure may require catheter replacement, increasing healthcare resource use and cost (eg, new catheters, nursing time) and delaying time-sensitive treatment for patients such as chemotherapy or antibiotic administration.13,14 Repeated PIVC failure can also lead to patients needing central venous access devices that are already associated with higher risk of complications and cost.15
Several national organizations provide guidelines for proper PIVC insertion and for prevention and management of catheter-related infections,16–18 yet nurses typically receive little instruction in PIVC insertion and only about 57% of nursing students receive PIVC training.19,20 In addition, executive-level hospital staff may be unaware of complications due to PIVC and the need for additional nurse training,21 and they may not consider PIVC-associated complications to be an area for improvement.22
This study sought to examine the prevalence of PIVC-associated complications in a large national sample of surgical patients and assess their burden on healthcare by comparing hospitalization cost, length of stay (LOS), and 30-day readmission risk between patients with complications and those without.
METHODS
Data Source
This study used data from the Premier Healthcare Database (PHD). The PHD is an all-payer hospital administrative database containing more than 1.5 billion inpatient and outpatient encounters from over 1300 geographically diverse hospitals in the United States. The standard hospital discharge files include patient demographics, disease states, and time-stamped log of billed services, including medications, laboratory, diagnostics, and therapeutic services at the patient-level, and hospital characteristics including geographic location, urbanicity of served population, teaching status, and bed capacity. All discharge data are statistically deidentified and compliant with the Health Insurance Portability and Accountability Act (HIPAA). Based on 45 CFR § 46, the study was exempted from institutional review board approval. We did not pursue informed consent of study participants due to the nature of de-identified data. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)23 reporting guideline.
Study Design and Population
This was a retrospective observational study of adult (age ≥18 years) and pediatric (age <18 years) surgical inpatients discharged between January 1, 2019, and December 31, 2023. Surgical inpatients were defined based on the presence of a Medicare Severity Diagnostic Related Group surgical code. Patients with peripherally inserted central catheter (PICC) or a central venous catheter (CVC) during the same hospitalization were excluded. Patients with multiple surgical inpatient discharges and those from hospitals without continuous data submission during the 180-day look-back and 30-day follow-up periods were excluded as well.
Study Measures
The primary outcome was PIVC-associated complications, which included BSI, extravasation including infiltration, upper extremity cellulitis, upper extremity phlebitis, acute embolism or thrombosis, and vascular complications following infusion, transfusion, or therapeutic injection. PIVC-associated complications were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) (Supplementary Table S1). If a patient had any of these complications, they were considered as having a PIVC-associated complication. Secondary outcomes included total hospital LOS, total hospitalization cost (all cost incurred in the hospital during the hospitalization), and 30-day risk of all-cause readmission (percentage of patients experiencing any hospitalization during the 30-day follow-up period).
Baseline patient characteristics including age, sex, race, ethnicity, insurance payer, and hospital characteristics including urbanicity of served population, teaching status, geographic region, and hospital size were provided by the hospitals. Charlson-Deyo comorbidities for adults and Feudtner Complex Chronic Conditions for pediatric patients were identified during hospitalization and during any visit to the same hospital within 180 days prior to the hospitalization using ICD-10-CM and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) codes.24–26 Charlson-Deyo Comorbidity Index score was calculated using a previously validated method.24,27 Cost variables were set to 96% winsorization (ie, all observations were set to have a maximum value at the 98th percentile and a minimum value at the 2nd percentile). All costs were adjusted to 2023 US dollars based on the Consumer Price Index for hospital services.28,29
Statistical Analysis
Descriptive statistics were used to present baseline patient and hospital characteristics of hospitalized surgical patients and their outcomes. All analyses for adult and pediatric cohorts were conducted separately. Continuous variables were reported as mean (standard deviation [SD]) or median (first quartile, third quartile), and categorical variables were reported as counts and percentages. For statistical difference between two groups, the Student’s t-test or Mann-Whitney test was used for continuous variables, as indicated, and Pearson’s χ2 test for categorical variables.
For the primary outcome, we assessed the prevalence of PIVC-associated complications overall and for each category (BSI, extravasation including infiltration, upper extremity cellulitis, upper extremity phlebitis, acute embolism or thrombosis, and vascular complications following infusion, transfusion, and therapeutic injection). For the secondary outcomes, we stratified each cohort by PIVC-associated complication status (with complication vs without complication) and then compared the differences in LOS, total hospitalization cost, and risk of all-cause readmissions within 30 days.
Adjusted analyses to assess independent association between PIVC-associated complications and secondary outcomes were conducted using multivariable linear regression models for continuous variables (total hospitalization cost and LOS) and multivariable logistic regression models for binary variable (risk of readmission within 30 days). A priori covariates for the adult cohort were patient demographics (sex, race, ethnicity, age, insurance payer), hospital characteristics (urbanicity of served population, hospital size, teaching status, geographic region), and clinical characteristics (surgical site infection, Charlson-Deyo comorbidities). A priori covariates for the pediatric cohort included patient demographics (sex, race, ethnicity, age, insurance payer), hospital characteristics (urbanicity of served population, hospital size, teaching status, geographic region), and clinical characteristics (surgical site infection, Feudtner Complex Chronic Conditions). The final list of covariates was selected using backward selection, and only those with statistical significance at the .05 level were included in the final regression models.
All analyses were performed using R version 4.1.3 (R Foundation for Statistical Computing).
RESULTS
We identified 7 151 376 hospitalized surgical patients meeting the study selection criteria (Figure S1). Of these, 6 992 120 (97.8%) patients were adults and 159 256 (2.2%) patients were children.
In the adult cohort, patients with PIVC-associated complications were older (mean age, 64.2 vs 55.2 years) and more likely to be men (53.1% vs 36.6%) and have Medicare (58.1% vs 40.5%) than those without complications (all P < .01). Patients with PIVC-associated complications were more likely to be treated in a large (43.8% vs 38.4%), teaching (61.1% vs 56.1%), and urban (92.4% vs 91.5%) hospital, and less likely to be discharged to home/home health (47.2% vs 84.6%) relative to patients without complications (all P < .01) (Table 1 and Supplementary Table S2A). Compared with patients without complications, those with PIVC-associated complications were more likely to have renal disease (49.2% vs 15.9%), chronic pulmonary disease (26.8% vs 16.6%), congestive heart failure (25.3% vs 9.4%), diabetes with chronic complication (21.7% vs 10.2%), and malignancy (17.4% vs 9.0%) (all P < .01).
Table 1. Patient Demographics, Clinical Characteristics, and Hospital Characteristics of Adult and Pediatric Surgical Inpatients with PIVC-Associated Complications.
| Characteristics | Overall | Patients with PIVC-Associated Complications | Patients without PIVC-Associated Complications | P |
|---|---|---|---|---|
| Adult cohort | N = 6 992 120 | N = 51 294 | N = 6 940 826 | |
| Mean age (SD), y | 55.3 (20) | 64.2 (17) | 55.2 (20) | <.0001 |
| Gender, n (%) | ||||
| Male | 2 569 108 (36.8) | 27 239 (53.1) | 2 541 869 (36.6) | <.0001 |
| Female | 4 421 303 (63.2) | 24 046 (46.9) | 4 397 257 (63.4) | |
| Race, n (%) | ||||
| White | 5 096 804 (72.9) | 35 554 (69.3) | 5 061 250 (72.9) | <.0001 |
| Black | 904 883 (12.9) | 8241 (16.1) | 896 642 (12.9) | |
| Other/unknown | 990 433 (14.2) | 7499 (14.6) | 982 934 (14.2) | |
| Ethnicity, n (%) | ||||
| Hispanic | 825 112 (11.8) | 5525 (10.8) | 819 587 (11.8) | <.0001 |
| Non-Hispanic | 5 325 717 (76.2) | 38 597 (75.2) | 5 287 120 (76.2) | |
| Unknown | 841 291 (12.0) | 7172 (14.0) | 834 119 (12.0) | |
| Health insurance type, n (%) | ||||
| Medicare | 2 844 190 (40.7) | 29 814 (58.1) | 2 814 376 (40.5) | <.0001 |
| Medicaid | 1 246 771 (17.8) | 8023 (15.6) | 1 238 748 (17.8) | |
| Private insurance | 2 390 314 (34.2) | 10 205 (19.9) | 2 380 109 (34.3) | |
| Uninsured | 226 795 (3.2) | 1531 (3.0) | 225 264 (3.2) | |
| Other/unknown | 284 050 (4.1) | 1721 (3.4) | 282 329 (4.1) | |
| Charlson-Deyo comorbidities, n (%) | ||||
| Myocardial infarction | 359 453 (5.1) | 5745 (11.2) | 353 708 (5.1) | <.0001 |
| Congestive heart failure | 663 037 (9.5) | 12 985 (25.3) | 650 052 (9.4) | <.0001 |
| Peripheral vascular disease | 299 420 (4.3) | 4793 (9.3) | 294 627 (4.2) | <.0001 |
| Cerebrovascular disease | 324 590 (4.6) | 6626 (12.9) | 317 964 (4.6) | <.0001 |
| Dementia | 241 240 (3.5) | 4598 (9.0) | 236 642 (3.4) | <.0001 |
| Chronic pulmonary disease | 1 165 700 (16.7) | 13 748 (26.8) | 1 151 952 (16.6) | <.0001 |
| Rheumatic disease | 143 958 (2.1) | 1478 (2.9) | 142 480 (2.1) | <.0001 |
| Peptic ulcer disease | 50 877 (0.7) | 1881 (3.7) | 48 996 (0.7) | <.0001 |
| Mild liver disease | 202 156 (2.9) | 2467 (4.8) | 199 689 (2.9) | <.0001 |
| Diabetes without chronic complication | 796 311 (11.4) | 7089 (13.8) | 789 222 (11.4) | <.0001 |
| Diabetes with chronic complication | 719 147 (10.3) | 11 134 (21.7) | 708 013 (10.2) | <.0001 |
| Hemiplegia or paraplegia | 94 926 (1.4) | 3006 (5.9) | 91 920 (1.3) | <.0001 |
| Renal disease | 1 128 249 (16.1) | 25 244 (49.2) | 1 103 005 (15.9) | <.0001 |
| Moderate/severe liver disease | 73 537 (1.1) | 2894 (5.6) | 70 643 (1.0) | <.0001 |
| Any malignancy | 637 016 (9.1) | 8923 (17.4) | 628 093 (9.0) | <.0001 |
| Metastatic solid tumor | 199 547 (2.9) | 4054 (7.9) | 195 493 (2.8) | <.0001 |
| HIV disease | 9653 (0.1) | 219 (0.4) | 9434 (0.1) | <.0001 |
| CCI score category | ||||
| 0 | 3 283 879 (47.0) | 7649 (14.9) | 3 276 230 (47.2) | <.0001 |
| 1-2 | 2 097 890 (30.0) | 12 838 (25.0) | 2 085 052 (30.0) | |
| >2 | 1 610 351 (23.0) | 30 807 (60.1) | 1 579 544 (22.8) | |
| Mean CCI score (SD) | 1.56 (2) | 3.75 (3) | 1.54 (2) | <.0001 |
| Pediatric cohort | N=159 256 | N = 816 | N = 158 440 | |
| Mean age (SD), y | 9.5 (6) | 8.6 (6) | 9.6 (6) | <.0001 |
| Gender, n (%) | ||||
| Male | 85 610 (53.8) | 433 (53.1) | 85 177 (53.8) | 0.6867 |
| Female | 73 617 (46.2) | 383 (46.9) | 73 234 (46.2) | |
| Race, n (%) | ||||
| White | 95 889 (60.2) | 485 (59.4) | 95 404 (60.2) | 0.0011 |
| Black | 24 862 (15.6) | 162 (19.9) | 24 700 (15.6) | |
| Other | 38 505 (24.2) | 169 (20.7) | 38 336 (24.2) | |
| Ethnicity, n (%) | ||||
| Hispanic | 38 721 (24.3) | 167 (20.5) | 38 554 (24.3) | <.0001 |
| Non-Hispanic | 101 121 (63.5) | 401 (49.1) | 100 720 (63.6) | |
| Unknown | 19 414 (12.2) | 248 (30.4) | 19 166 (12.1) | |
| Health insurance type, n (%) | ||||
| Medicare | 235 (0.1) | 3 (0.4) | 232 (0.1) | <.0001 |
| Medicaid | 88 446 (55.5) | 497 (60.9) | 87 949 (55.5) | |
| Private insurance | 60 161 (37.8) | 262 (32.1) | 59 899 (37.8) | |
| Uninsured | 3791 (2.4) | 35 (4.3) | 3756 (2.4) | |
| Other/unknown | 6623 (4.2) | 19 (2.3) | 6604 (4.2) | |
| Feudtner Complex Chronic Conditions, n (%) | ||||
| Neurologic and neuromuscular | 14 874 (9.3) | 119 (14.6) | 14 755 (9.3) | <.0001 |
| Cardiovascular | 13 334 (8.4) | 163 (20.0) | 13 171 (8.3) | <.0001 |
| Respiratory | 4870 (3.1) | 88 (10.8) | 4782 (3.0) | <.0001 |
| Renal and urologic | 5664 (3.6) | 52 (6.4) | 5612 (3.5) | <.0001 |
| Gastrointestinal | 12 930 (8.1) | 175 (21.4) | 12 755 (8.1) | <.0001 |
| Hematologic or immunologic | 3781 (2.4) | 73 (8.9) | 3708 (2.3) | <.0001 |
| Metabolic | 5138 (3.2) | 106 (13.0) | 5032 (3.2) | <.0001 |
| Other congenital or genetic defect | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA |
| Premature and neonatal | 1817 (1.1) | 51 (6.2) | 1766 (1.1) | <.0001 |
| Malignancy | 4670 (2.9) | 45 (5.5) | 4625 (2.9) | <.0001 |
| Technology dependence | 14 308 (9.0) | 185 (22.7) | 14 123 (8.9) | <.0001 |
| Solid organ/bone marrow transplantation | 609 (0.4) | 13 (1.6) | 596 (0.4) | <.0001 |
Abbreviations: CCI, Charlson-Deyo Comorbidity Index; NA, not applicable; PIVC, peripheral intravenous catheter.
In the pediatric cohort, patients with PIVC-associated complications were younger (mean age, 8.6 vs 9.6 years), more likely to be Black (19.9% vs 15.6%) and have Medicaid (60.9% vs 55.5%) than those without complications (all P < .01). Patients with complications were treated more often in teaching (85.3% vs 76.8%) and urban (98.3% vs 96.4%) hospitals and were less likely to be discharged to home/home health (86.5% vs 97.6%) (all P < .01) (Table 1 and Supplementary Table S2B).
Patients with PIVC-associated complications were more likely to have technology dependence (22.7% vs 8.9%), gastrointestinal disorders (21.4% vs 8.1%), cardiovascular diseases (20.0% vs 8.3%), and neurologic or neuromuscular conditions (14.6% vs 9.3%) than their counterparts without complications (all P < .01).
PIVC-Associated Complications
The prevalence of having any PIVC-associated complication was 0.70% among adult patients and 0.50% among pediatric patients (Table 2). BSI accounted for the majority of the complications in both adult (71.1%) and pediatric populations (71.8%). The prevalences of extravasation including infiltration, upper extremity cellulitis, upper extremity phlebitis, acute embolism/thrombosis, and vascular complications ranged from 0.02% to 0.12% in adults and from 0.01% to 0.06% in pediatric patients (Table 2).
Table 2. PIVC-Associated Complications and Healthcare Resource Use and Cost of Surgical Inpatients.
| Outcomes | Overall | Patients with PIVC-Associated Complications | Patients without PIVC-Associated Complications | P |
|---|---|---|---|---|
| Adult cohort | N = 6 992 120 | N = 51 294 | N = 6 940 826 | |
| Prevalences of PIVC-associated complications, n (%) | ||||
| Any | 51 294 (0.70) | |||
| BSI | 36 495 (0.52) | |||
| Extravasation including infiltration | 2492 (0.04) | |||
| Upper extremity cellulitis | 1666 (0.02) | |||
| Upper extremity phlebitis | 4477 (0.06) | |||
| Acute embolism/thrombosis | 8240 (0.12) | |||
| Vascular complications | 1054 (0.02) | |||
| Healthcare resource use | ||||
| Total LOS during hospitalization (days) | ||||
| Mean (SD) | 4.06 (3.77) | 12.50 (6.65) | 3.99 (3.67) | <.0001 |
| Median (Q1-Q3) | 3 (2-5) | 11 (7-19) | 3 (2-5) | |
| Readmissions and outpatient visits during 30-day follow-up, n (%) | ||||
| All-cause readmissions | 426 286 (6.1) | 6186 (13.5) | 420 100 (6.1) | <.0001 |
| All-cause outpatient visits | 1 322 760 (19.0) | 10 411 (22.8) | 1 312 349 (19.0) | <.0001 |
| BSI-related readmissions | 67 771 (1.0) | 1777 (3.9) | 65 994 (1.0) | <.0001 |
| BSI-related outpatient visits | 130 (0.0) | 1 (0.0) | 129 (0.0) | 0.616 |
| Healthcare cost | ||||
| Total hospitalization cost (2023 US $) | ||||
| Mean (SD) | 20 695 (16 764) | 48 624 (29 917) | 20 489 (16 452) | <.0001 |
| Median (Q1-Q3) | 15 645 (10 259-24 760) | 40 130 (24 087-69 867) | 15 574 (10 227-24 551) | |
| Total cost for all-cause readmission during 30-day follow-up (2023 US $) | ||||
| Mean (SD) | 18 205 (18 796) | 26 017 (25 814) | 18 117 (18 683) | <.0001 |
| Median (Q1-Q3) | 12 164 (6875-22 044) | 16 545 (8809-32 979) | 12 128 (6859-21 944) | |
| Total cost for all-cause outpatient visits during 30-day follow-up (2023 US $) | ||||
| Mean (SD) | 1813 (3333) | 2094 (3478) | 1811 (3332) | <.0001 |
| Median (Q1-Q3) | 560 (166-1713) | 725 (212-2311) | 559 (166-1708) | |
| Pediatric cohort | N=159 256 | N = 816 | N = 158 440 | |
| Prevalences of PIVC-associated complications, n (%) | ||||
| Any | 816 (0.50) | |||
| BSI | 586 (0.37) | |||
| Extravasation including infiltration | 95 (0.06) | |||
| Upper extremity cellulitis | 31 (0.02) | |||
| Upper extremity phlebitis | 56 (0.04) | |||
| Acute embolism/thrombosis | 80 (0.05) | |||
| Vascular complications | 8 (0.01) | |||
| Healthcare resource use | ||||
| Total LOS during hospitalization (days) | ||||
| Mean (SD) | 3.57 (3.74) | 10.41 (7.66) | 3.54 (3.68) | <.0001 |
| Median (Q1-Q3) | 2 (1-4) | 7 (4-19) | 2 (1-4) | |
| Readmissions and outpatient visits during 30-day follow-up, n (%) | ||||
| All-cause readmissions | 7870 (5.0) | 105 (13.2) | 7765 (4.9) | <.0001 |
| All-cause outpatient visits | 30 486 (19.2) | 216 (27.2) | 30 270 (19.1) | <.0001 |
| BSI-related readmissions | 477 (0.3) | 14 (1.8) | 463 (0.3) | <.0001 |
| BSI-related outpatient visits | 1 (0.0) | 0 (0.0) | 1 (0.0) | 0.99 |
| Healthcare cost | ||||
| Total hospitalization cost (2023 US $) | ||||
| Mean (SD) | 20 542 (20 473) | 46 610 (36 758) | 20 408 (20 270) | <.0001 |
| Median (Q1-Q3) | 13 191 (8483-23 055) | 30 260 (13 826-90 624) | 13 160 (8468-22 928) | |
| Total cost for all-cause readmission during 30-day follow-up (2023 US $) | ||||
| Mean (SD) | 15 922 (19 812) | 36 415 (34 753) | 15 785 (19 604) | <.0001 |
| Median (Q1-Q3) | 9429 (6192-15 811) | 21 852 (11 763-50 354) | 9391 (6181-15 713) | |
| Total cost for all-cause outpatient visits during 30-day follow-up (2023 US $) | ||||
| Mean (SD) | 1561 (2986) | 2237 (3876) | 1556 (2978) | 0.0112 |
| Median (Q1-Q3) | 451 (166-1354) | 769 (323-2062) | 450 (166-1351) | |
Abbreviations: BSI, bloodstream infection; CCI, Charlson-Deyo Comorbidity Index; LOS, length of stay; NA, not applicable; PIVC, peripheral intravenous catheter.
Readmissions Within 30 Days
In the adult cohort, a total of 426 286 patients (6.1%) were readmitted within 30 days after hospitalization (Table 2). A higher proportion of patients with PIVC-associated complications were readmitted for any reason (13.5% vs 6.1%, P < .01) compared with those without complications. Patients with PIVC-associated complications were also more likely to have all-cause outpatient visits (22.8% vs 19.0%, P < .01) and BSI-related readmissions (3.9% vs 1.0%, P < .01) within 30 days than those without complications. After adjusting for covariates, patients with PIVC-associated complications were still 46% more likely to be readmitted for any reason than those without complications (adjusted odds ratio [aOR], 1.46; 95% confidence interval [CI], 1.42-1.50) (Table 3).
Table 3. 30-Day All-Cause Readmission Outcome Associated with PIVC-Associated Complications.
| Unadjusted OR (95% CI) | Adjusted OR (95% CI) | |||
|---|---|---|---|---|
| With PIVC-Associated Complications | Without PIVC-Associated Complications | With PIVC-Associated Complications | Without PIVC-Associated Complications | |
| 30-day all-cause readmission | ||||
| Adult patientsa | 2.13 (2.07-2.19) | 1.00 (-) | 1.46 (1.42-1.50) | 1.00 (-) |
| Pediatric patientsb | 2.67 (2.33-3.52) | 1.00 (-) | 2.15 (1.73-2.67) | 1.00 (-) |
Abbreviations: CI, confidence interval; OR, odds ratio; PIVC, peripheral intravenous catheter.
aAdjusted for sex, race, age group, ethnicity, insurance, urbanicity of served population, hospital size, hospital teaching status, geographic region, surgical site infection, diabetes, congestive heart failure, chronic pulmonary disease, renal disease, malignancy, and Charlson Comorbidity Index score.
bAdjusted for sex, age group, ethnicity, insurance, urbanicity of served population, hospital size, hospital teaching status, geo-graphic region, surgical site infection, and complex chronic conditions (neurologic and neuromuscular, cardiovascular, gastrointestinal, and technology dependence).
Among the pediatric cohort, a total of 7870 patients (5.0%) were readmitted within 30 days following the hospitalization (Table 2). A higher proportion of those patients with PIVC-associated complications were readmitted for any reason (13.2% vs 4.9%, P < .01) compared to those without complications. Patients with PIVC-associated complications had higher rates of all-cause outpatient visits (27.2% vs 19.1%, P < .01) and BSI-related readmissions (1.8% vs 0.3%, P < .01) within 30 days than those without complications. After adjusting for covariates, patients with PIVC-associated complications had a 115% higher risk of readmission for any reason than those without complications (aOR, 2.15; 95% CI, 1.73-2.67) (Table 3).
Hospital Length of Stay
In the adult cohort, the mean LOS was longer for patients with PIVC-associated complications than for those without (12.50 vs 3.99 days, P < .01) (Tables 2 and 4). After adjusting for covariates, the difference attenuated, but patients with PIVC-associated complications still had longer LOS by 5.52 days than patients without complications.
Table 4. Length of Stay and Total Hospitalization Cost Outcomes During Hospitalization Associated with PIVC-Associated Complications.
| N | Unadjusted Means (SD) | Adjusted Means (SD) | Difference (SD) | Ratio (95% CI) | |||
|---|---|---|---|---|---|---|---|
| With PIVC-Associated Complications | Without PIVC-Associated Complications | With PIVC-Associated Complications | Without PIVC-Associated Complications | ||||
| Length of hospital stay (days) | |||||||
| Adult patientsa | 6 992 120 | 12.50 (6.65) | 3.99 (3.67) | 9.53 (3.13) | 4.00 (1.32) | 5.52 (1.82) |
2.38 (2.37-2.39) |
| Pediatric patientsb | 159 256 | 10.41 (7.66) | 3.54 (3.68) | 8.04 (3.23) | 3.55 (1.43) | 4.50 (1.81) |
2.27 (2.17-2.37) |
| Total hospitalization cost, US $ | |||||||
| Adult patientsa | 6 959 775 | 48 624 (29 917) | 20 489 (16 452) | 39 626 (12 546) | 20 551 (6507) | 19 074 (6040) |
1.93 (1.92-1.94) |
| Pediatric patientsb | 158 867 | 46 610 (36 758) | 20 407 (20 270) | 36 659 (17 507) | 20 607 (9841) | 16 052 (7666) |
1.78 (1.67-1.89) |
Abbreviations: CI, confidence interval; PIVC, peripheral intravenous catheter.
aAdjusted for sex, race, age group, ethnicity, insurance, urbanicity of served population, hospital size, hospital teaching status, geographic region, surgical site infection, diabetes, congestive heart failure, chronic pulmonary disease, renal disease, malignancy, and Charlson Comorbidity Index score.
bAdjusted for race, age group, ethnicity, insurance, urbanicity of served population, hospital size, hospital teaching status, geographic region, surgical site infection, and complex chronic conditions (neurologic and neuromuscular, cardiovascular, gastrointestinal, and technology dependence).
cAdjusted for sex, race, age group, ethnicity, insurance, urbanicity of served population, hospital size, hospital teaching status, geographic region, surgical site infection, diabetes, congestive heart failure, chronic pulmonary disease, renal disease, malignancy, and Charlson Comorbidity Index score.
dAdjusted for sex, race, age group, ethnicity, insurance, urbanicity of served population, hospital size, hospital teaching status, geographic region, surgical site infection, and complex chronic conditions (neurologic and neuromuscular, cardiovascular, gastrointestinal, and technology dependence).
Similarly in the pediatric cohort, the mean LOS was longer for patients with PIVC-associated complications compared with those without (10.41 vs 3.54 days, P < .01) (Tables 2 and 4). After adjusting for covariates, patients with PIVC-associated complications still had longer LOS by 4.50 days than those without complications.
Total Hospitalization Cost
In the adult cohort, the mean total hospitalization cost was substantially higher among patients with PIVC-associated complications compared to those without ($48 624 vs $20 489, P < .01) (Tables 2 and 4). The total hospitalization cost for each type of PIVC-associated complications was higher than that of patients without complications, and the cost was the highest for patients with acute embolism/thrombosis (Figure 1a). Although the difference attenuated after adjusting for covariates, patients with PIVC-associated complications incurred 93% higher cost (adjusted cost ratio, 1.93; 95% CI, 1.92-1.94) than those without complications, amounting to the adjusted mean difference of $19 074.
Figure 1. Hospitalization Cost Between Surgical Inpatients with and without Peripheral Intravenous Catheter–Associated Complications, for Adult (a) and Pediatric (b) Cohorts.
Similarly in the pediatric cohort, the mean total hospitalization cost was significantly higher among patients with PIVC-associated complications compared to those without ($46 610 vs $20 407, P < .01) (Tables 2 and 4). As with the adult cohort, the total hospitalization cost was the highest for pediatric patients with acute embolism/thrombosis (Figure 1b). Following adjustment for covariates, patients with PIVC-associated complications incurred 78% higher cost (adjusted cost ratio, 1.78; 95% CI, 1.67-1.89) than those without, amounting to the adjusted mean difference of $16 052.
DISCUSSION
This large, retrospective observational analysis of hospitalized surgical patients indicates evidence of PIVC-associated complications and their healthcare burden. While the overall prevalence of PIVC-associated complications may seem low at around 1%, this still amounts to a significant number of patients (eg, ~52 000 patients just in this study), as most patients undergoing an inpatient surgical procedure would have a PIVC placed. The results from this study indicated that patients with PIVC-associated complications were more likely to be hospitalized longer, readmitted within 30 days, and incur higher hospitalization cost than patients without these complications. This observation was consistent for both adult and pediatric patients, and before and after adjusting for potential confounders.
Lim et al30 reported that about 2% of 588 375 hospitalized patients with pneumonia, chronic obstructive pulmonary disease, myocardial infarction, congestive heart failure, chronic kidney disease, diabetes with complications, and major trauma developed PIVC-associated complications. Among these various conditions, patients with pneumonia, diabetes, or myocardial infarction had the highest prevalence of complications. The prevalence of PIVC-associated complications was lower (~1%) in our study, which is plausible as our study population would have been relatively healthier to undergo a surgical procedure compared to the population who had been hospitalized for infections and chronic conditions. Almost half of our adult study population had no chronic conditions as evidenced by Charlson-Deyo Comorbidity Index score of zero. This is also similar to reporting of Lim et al30 that the prevalence of PIVC-associated complications among major trauma patients was 1.03%.
We found that among different types of PIVC-associated complications, BSI was most prevalent (0.52% in the adult cohort and 0.37% in the pediatric cohort), which is consistent with the findings by Lim et al.30 Prevalence of PIVC-associated BSI in this study is higher than that in a systemic review and meta-analysis by Marsh et al1 (1 in 5606). However, as the authors stated, PIVC-associated BSIs often do not present signs and symptoms, necessitating prompt tip cultures that leads to accurate diagnosis. This most likely resulted in underestimations for clinical studies included in the meta-analysis (as opposed to this study and the Lim et al study using real-world data).30 Even at a rate of 1 in 5606 (~0.02%) for PIVC-associated BSI, Marsh et al1 argued that it is comparable to the rate of PICC- and CVC-related BSIs, given the enormous volume of PIVC use.
We note that a systemic review of complications associated with with long peripheral catheters showed that the most common complications were catheter occlusion (4%), followed by phlebitis (1%), infiltration (0.9%), and catheter-associated BSI (0.3%).3 Because our study used a real-world hospital administrative database, it is possible that complications such as catheter occlusion and infiltration, which are often perceived as less severe but potentially clinically significant, were underreported.
While discrepancies exist in the magnitude of healthcare burden across different studies, this study and others suggest that PIVC-associated complications are costly and a significant burden to hospitals.
Studies have called to action on reducing PIVC-associated complications through a multistage approach: by identifying it as a public health problem, developing and implementing quality measures and best practices for the insertion of PIVC, and creating federal and state prevention programs similarly to the successful approaches taken for central line-associated BSIs.1,30–32
We want to add that establishing a formal mechanism to better track the incidence of PIVC-associated BSIs, thus leading to robust prevention programs and enhanced care, could be a practical investment for all stakeholders in the US healthcare system.
This study is not without limitations. First, the use of PIVC was inferred rather than directly observed. Because the use of PIVC is difficult to capture in real-world data, we assumed that all inpatient surgical procedures require vascular access for administering anesthesia. By excluding patients with PICCs or CVCs, we further assumed that all remaining patients had a PIVC in place. Based on the literature and clinical expert input, the placement of a PIVC in every patient upon admission is a standard practice.30 Because we expected all patients included in the study to have a PIVC placed, misclassification of PIVC use is possible if some surgical patients did not receive a PIVC. Second, complications were identified using ICD-10 codes and may have undercaptured less severe but clinically relevant events (eg, occlusion or infiltration) and may have been subject to variability in coding practices across hospitals. The resulting association due to misclassification of undercaptured events is likely biased toward the null. Third, the timing of complications relative to outcomes occurring during the hospitalization (ie, LOS and total hospitalization cost) could not be determined and included days and costs prior to the complication, limiting causal attribution. As with the nature of real-world data study, because the date of complication is difficult to determine without the presence of clinical notes and because patients without complications would not have reference dates, it was not possible to capture outcomes only happening after the complication during hospitalization. By adjusting for appropriate baseline conditions and confounders, the difference in outcomes is expected to be the effect of PIVC-associated complications. Fourth, readmissions and outpatient visits to the same hospital or health system are captured, but visits to a different PHD hospital during the follow-up period may have been missed. Because the observation period is short for this study, attrition due to relocation is not expected, and patients were expected to return to the same hospital if they experienced any health issues after discharge. Therefore, the frequency of missed visits to a different hospital is expected to be very low. Lastly, residual confounding is possible, as important factors such as catheter dwell time, number of insertion attempts, and provider skill were not captured and because variable selection was based on statistical significance. However, a priori variable selection was based on clinical relevance, and retaining all covariates regardless of P value did not change the interpretation of the results.
CONCLUSIONS
This study indicated that PIVC-associated complications were associated with increased cost, extended hospital length of stay and increased risk of readmission during 30-day follow-up in both adult and pediatric surgical inpatients in the United States. This is one of the first few studies to report on the real-world costs to hospitals associated with PIVC-associated complications among inpatients undergoing surgeries. The results of this study can serve as a catalyst for stakeholders to establish a process for decreasing complications related to the use of PIVCs. A comprehensive understanding of the implications to patients, healthcare providers, and payers requires an investment in detailed research to quantify the magnitude of the problem, explore causality, and most importantly, determine those complications that are potentially avoidable when considered with fiscally responsible solutions.
Disclosures
S.P. and K.J. are employees of B. Braun Medical Inc. B. Braun Medical Inc. contracted Premier, Inc. to conduct this study. J.G., R.M., J.D., and N.R. worked on this study as employees of Premier Inc.
Supplementary Material
Acknowledgments
The authors wish to recognize the valuable contributions from David Banko in initiating and providing insights into the manuscript. We thank Rheana Lipscomb and Cate Polacek for administrative assistance on this manuscript.
Funding Statement
This research project was funded by B. Braun Medical Inc., Bethlehem, Pennsylvania. The funder had a role in the design and conduct of the study; management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript, as well as the decision to submit the manuscript for publication. However, the funder had no role in collection of the data.
References
- 1.Peripheral intravenous catheter infection and failure: a systematic review and meta-analysis. Marsh N., Larsen E. N., Ullman A. J.., et al. 2024Int J Nurs Stud. 151:104673. doi: 10.1016/j.ijnurstu.2023.104673. https://doi.org/10.1016/j.ijnurstu.2023.104673 [DOI] [PubMed] [Google Scholar]
- 2.Vascular access devices market size, share and trends analysis, global, 2024-2030. iData Research; [2025-11-7]. https://idataresearch.com/product/vascular-access-devices-market/ [Google Scholar]
- 3.Long peripheral catheters for deep arm vein venous access: a systematic review of complications. Badger J. 2019Heart Lung. 48(3):222–225. doi: 10.1016/j.hrtlng.2019.01.002. https://doi.org/10.1016/j.hrtlng.2019.01.002 [DOI] [PubMed] [Google Scholar]
- 4.Evaluation of Skin Colonisation And Placement of vascular access device Exit sites (ESCAPE Study) Moureau N. L., Marsh N., Zhang L.., et al. 2019J Infect Prev. 20(1):51–59. doi: 10.1177/1757177418805836. https://doi.org/10.1177/1757177418805836 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Guidelines for the prevention of intravascular catheter-related infections. O'Grady N. P., Alexander M., Burns L. A.., et al. 2011Am J Infect Control. 39(4 suppl 1):S1–34. doi: 10.1016/j.ajic.2011.01.003. https://doi.org/10.1016/j.ajic.2011.01.003 [DOI] [PubMed] [Google Scholar]
- 6.Blood stream infections associated with central and peripheral venous catheters. Ruiz-Giardin J. M., Ochoa Chamorro I., Velazquez Rios L.., et al. 2019BMC Infect Dis. 19(1):841. doi: 10.1186/s12879-019-4505-2. https://doi.org/10.1186/s12879-019-4505-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Short peripheral venous catheters contamination and the dangers of bloodstream infection in Portugal: an analytic study. Osorio N., Oliveira V., Costa M. I.., et al. 2023Microorganisms. 11(3) doi: 10.3390/microorganisms11030709. https://doi.org/10.3390/microorganisms11030709 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Short-term peripheral venous catheter-related bloodstream infections: a systematic review. Mermel L. A. 2017Clin Infect Dis. 65(10):1757–1762. doi: 10.1093/cid/cix562. https://doi.org/10.1093/cid/cix562 [DOI] [PubMed] [Google Scholar]
- 9.National Healthcare Safety Network CDC/NHSN Surveillance Definitions for Specific Types of Infections. [2025-10-24]. https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf
- 10.National Healthcare Safety Network Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection) [2025-10-24]. https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf
- 11.Intravenous therapy: a review of complications and economic considerations of peripheral access. Dychter S. S., Gold D. A., Carson D., Haller M. 2012J Infus Nurs. 35(2):84–91. doi: 10.1097/NAN.0b013e31824237ce. https://doi.org/10.1097/NAN.0b013e31824237ce [DOI] [PubMed] [Google Scholar]
- 12.Peripheral vein thrombophlebitis in the upper extremity: a systematic review of a frequent and important problem. Heng S.Y., Yap R.T., Tie J., McGrouther D.A. 2020Am J Med. 133(4):473–484e3. doi: 10.1016/j.amjmed.2019.08.054. https://doi.org/10.1016/j.amjmed.2019.08.054 [DOI] [PubMed] [Google Scholar]
- 13.Peripheral intravenous catheter non-infectious complications in adults: a systematic review and meta-analysis. Marsh N., Webster J., Ullman A. J.., et al. 2020J Adv Nurs. 76(12):3346–3362. doi: 10.1111/jan.14565. https://doi.org/10.1111/jan.14565 [DOI] [PubMed] [Google Scholar]
- 14.Peripheral intravenous catheter assessment: beyond phlebitis. Rickard C. M., Ray-Barruel G. 2017Lancet Haematol. 4(9):e402–e403. doi: 10.1016/S2352-3026(17)30145-X. https://doi.org/10.1016/S2352-3026(17)30145-X [DOI] [PubMed] [Google Scholar]
- 15.The risk of bloodstream infection associated with peripherally inserted central catheters compared with central venous catheters in adults: a systematic review and meta-analysis. Chopra V., O'Horo J. C., Rogers M. A., Maki D. G., Safdar N. 2013Infect Control Hosp Epidemiol. 34(9):908–18. doi: 10.1086/671737. https://doi.org/10.1086/671737 [DOI] [PubMed] [Google Scholar]
- 16.Centers for Disease Control and Prevention Summary of Recommendations - Guidelines for the Prevention of Intravascular Catheter-Related Infections. [2025-10-23]. https://www.cdc.gov/infection-control/hcp/intravascular-catheter-related-infections/summary-recommendations.html?CDC_AAref_Val=https://www.cdc.gov/infectioncontrol/guidelines/bsi/recommendations.html
- 17.Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Mermel L. A., Allon M., Bouza E.., et al. Jul 1;2009 Clin Infect Dis. 49(1):1–45. doi: 10.1086/599376. https://doi.org/10.1086/599376 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Guidelines for the prevention of intravascular catheter-related infections. O'Grady N. P., Alexander M., Burns L. A.., et al. 2011Am J Infect Control. 39(4 Suppl 1):S1–34. doi: 10.1016/j.ajic.2011.01.003. https://doi.org/10.1016/j.ajic.2011.01.003 [DOI] [PubMed] [Google Scholar]
- 19.A simulation-based blended curriculum for short peripheral intravenous catheter insertion: an industry-practice collaboration. Glover K. R., Stahl B. R., Murray C.., et al. 2017J Contin Educ Nurs. 48(9):397–406. doi: 10.3928/00220124-20170816-05. https://doi.org/10.3928/00220124-20170816-05 [DOI] [PubMed] [Google Scholar]
- 20.Assessing nursing students' knowledge and skills in performing venepuncture and inserting peripheral venous catheters. Ahlin C., Klang-Soderkvist B., Johansson E., Bjorkholm M., Lofmark A. 2017Nurse Educ Pract. 23:8–14. doi: 10.1016/j.nepr.2017.01.003. https://doi.org/10.1016/j.nepr.2017.01.003 [DOI] [PubMed] [Google Scholar]
- 21.Complications of peripheral venous access devices: prevention, detection, and recovery strategies. Mattox E. A. 2017Crit Care Nurse. 37(2):e1–e14. doi: 10.4037/ccn2017657. https://doi.org/10.4037/ccn2017657 [DOI] [PubMed] [Google Scholar]
- 22.Premier Applied Sciences Optimizing first-stick success and peripheral IV catheter management. [2025-10-23]. https://bit.ly/3OFHGy8
- 23.The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. von Elm E., Altman D. G., Egger M.., et al. 2007Lancet. 370(9596):1453–7. doi: 10.1016/S0140-6736(07)61602-X. [DOI] [PubMed] [Google Scholar]
- 24.Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Deyo R. A., Cherkin D. C., Ciol M. A. 1992J Clin Epidemiol. 45(6):613–9. doi: 10.1016/0895-4356(92)90133-8. [DOI] [PubMed] [Google Scholar]
- 25.Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Quan H., Sundararajan V., Halfon P.., et al. 2005Med Care. 43(11):1130–9. doi: 10.1097/01.mlr.0000182534.19832.83. https://doi.org/10.1097/01.mlr.0000182534.19832.83 [DOI] [PubMed] [Google Scholar]
- 26.Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. Feudtner C., Feinstein J. A., Zhong W., Hall M., Dai D. 2014BMC Pediatr. 14:199. doi: 10.1186/1471-2431-14-199. https://doi.org/10.1186/1471-2431-14-199 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Rosenthal N., Cao Z., Chung J.., et al. Updated coding algorithm for assessing Charlson Comorbidity Index using large hospital administrative data; ISPOR 22nd Annual International Meeting; Boston, MA. [Google Scholar]
- 28.US Department of Labor, Bureau of Labor Statistics Inpatient hospital services consumer price index. [2025-10-29]. http://www.bls.gov/cpi/
- 29.Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Dunn A., Grosse S.D., Zuvekas S.H. 2018Health Serv Res. 53(1):175–196. doi: 10.1111/1475-6773.12612. https://doi.org/10.1111/1475-6773.12612 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Increased clinical and economic burden associated with peripheral intravenous catheter-related complications: analysis of a US hospital discharge database. Lim S., Gangoli G., Adams E.., et al. 2019Inquiry. 56:46958019875562. doi: 10.1177/0046958019875562. https://doi.org/10.1177/0046958019875562 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Peripheral venous catheter-related bloodstream infection is associated with severe complications and potential death: a retrospective observational study. Sato A., Nakamura I., Fujita H.., et al. 2017BMC Infect Dis. 17(1):434. doi: 10.1186/s12879-017-2536-0. https://doi.org/10.1186/s12879-017-2536-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.The I-DECIDED clinical decision-making tool for peripheral intravenous catheter assessment and safe removal: a clinimetric evaluation. Ray-Barruel G., Cooke M., Chopra V., Mitchell M., Rickard C. M. 2020BMJ Open. 10(1):e035239. doi: 10.1136/bmjopen-2019-035239. https://doi.org/10.1136/bmjopen-2019-035239 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.